Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 3/20 | 0.50 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.44 |
| ▸ | PPARA | Q07869 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5093626 | 0.92 | MTNR1A (0.49) | MTNR1AMTNR1BL3MBTL1ABCB1TDP1 | |
| SCHEMBL4381103 | 0.83 | MTNR1A (0.45) | MTNR1AMTNR1BL3MBTL1ALDH1A1 | |
| SCHEMBL20954700 | 0.80 | MTNR1A (0.58) | MTNR1AMTNR1BL3MBTL1ABCB1TDP1 | |
| SCHEMBL5446276 | 0.78 | L3MBTL1 (0.53) | MTNR1AMTNR1BL3MBTL1ALDH1A1ALOX5 | |
| SCHEMBL13760599 | 0.76 | ALDH1A1 (0.51) | L3MBTL1ALDH1A1ALOX5 | |
| SCHEMBL20954703 | 0.76 | MEN1 (0.51) | MTNR1AMTNR1BL3MBTL1ALDH1A1ALOX5 | |
| SCHEMBL20954710 | 0.76 | MTNR1A (0.47) | MTNR1AMTNR1BL3MBTL1ALDH1A1PPARA | |
| SCHEMBL20954694 | 0.75 | MTNR1A (0.48) | MTNR1AMTNR1BL3MBTL1ALDH1A1ALOX5 | |
| SCHEMBL4034898 | 0.75 | MTNR1A (0.54) | MTNR1AMTNR1BL3MBTL1ALDH1A1 | |
| SCHEMBL392863 | 0.75 | ALOX5 (0.66) | ALDH1A1ALOX5FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7348017-B2 | Dithiazole compounds, matrix metalloprotease inhibitors and external preparations for the skin | SHISEIDO CO., LTD. (JP) | 2008-03-25 | — | — | US | disclosed |
| EP-1422224-B1 | DITHIAZOLE COMPOUNDS, MATRIX METALLOPROTEASE INHIBITORS AND EXTERNAL PREPARATIONS FOR THE SKIN | SHISEIDO CO LTD (JP) | 2007-12-19 | — | — | EP | disclosed |
| US-20040236111-A1 | Dithiazole compounds, matrix metalloprotease inhibitors and external preparations for the skin | SHISEIDO CO., LTD. (JP) | 2004-11-25 | — | — | US | disclosed |
| EP-1422224-A1 | DITHIAZOLE COMPOUNDS, MATRIX METALLOPROTEASE INHIBITORS AND EXTERNAL PREPARATIONS FOR THE SKIN | Shiseido Co., Ltd. (JP) | 2004-05-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040236111-A1 | Dithiazole compounds, matrix metalloprotease inhibitors and external preparations for the skin | MMP1, MMP2, MMP3 | MTNR1A 3316/4885MTNR1B 3685/4885L3MBTL1 4768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.